-5%
Viglimet Tablet (Vildagliptin 50mg + Metformin HCI 500mg) is used to Treat Type 2 Diabetes Mellitus when vildagliptin or metformin alone, along with diet and exercise, are ineffective in controlling blood sugar.
Viglimet 50/500mg Tablet is a combination of Vildagliptin (DPP-4 inhibitor) and Metformin (Biguanides), used to treat type 2 diabetes mellitus. Type 2 diabetes develops when the body does not produce enough insulin or when insulin does not work effectively. Galvus Met helps control blood sugar levels by increasing insulin production and decreasing glucagon release. It is not a substitute for insulin and should not be used to treat type 1 diabetes or diabetic ketoacidosis.
To ensure its effectiveness, Viglimet 50/500mg Tablet should be taken with food and at the same time each day. Your doctor will determine the appropriate dose based on your condition, and it may need to be adjusted over time. The most common side effect is hypoglycemia, characterized by symptoms like dizziness, sweating, palpitations, and hunger. To prevent hypoglycemia, do not skip meals and carry a source of sugar with you.
It is important not to stop taking Viglimet 50/500mg Tablet abruptly, even if you feel better, as sudden discontinuation may lead to an increase in sugar levels and potential complications like eyesight loss, kidney problems, and nerve damage.
Viglimet 50/500mg Tablet should not be used in type 1 diabetes or severe kidney or liver disease. Inform your doctor if you have any heart disease or if you are planning to get pregnant or breastfeed.
Always follow your doctor’s instructions and continue to monitor your blood sugar levels while on Viglimet 50/500mg Tablet to effectively manage your diabetes. Metformin is a medication belonging to the class of drugs called Biguanides. It works by reducing the production of glucose in the liver, decreasing the absorption of glucose from the intestines, and improving insulin sensitivity in the body’s peripheral tissues. This results in improved glucose tolerance and lower levels of both fasting and post-meal blood glucose.
Vildagliptin, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It acts by blocking the action of DPP-4, an enzyme responsible for inactivating incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, vildagliptin prolongs the activity of these incretin hormones in response to food intake. This leads to increased insulin sensitivity, reduced glucagon secretion, and improved function of beta cells in the pancreas, which ultimately results in better glycemic control.
Together, the combination of metformin and vildagliptin helps control blood sugar levels in patients with type 2 diabetes by targeting different aspects of glucose metabolism and insulin regulation. This dual mechanism of action makes the combination effective in managing the condition and achieving better glucose control.